ArticleMedicine2026
Mediating effects of lipid metabolic and inflammatory factors on skeletal muscle mass in adults: A cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Investigating the mediating effects of metabolic and inflammatory factors on skeletal muscle mass is essential, as these factors may help deepen understanding of the complex processes underlying skeletal muscle mass decline and support effective prevention and management in adults. Health examination data from 2277 participants who attended the health examination center of a provincial hospital in Taiyuan, China, between 2019 and 2023 were collected. Random forest analysis, correlation analysis, regression modeling, and mixed-effects structural equation modeling were used to identify determinants of appendicular skeletal muscle index (ASMI) and to examine metabolic and inflammatory mediating pathways. ASMI was significantly higher in obese participants than in nonobese participants (P < .001). Body mass index (BMI) was significantly positively correlated with ASMI (r = 0.68, P < .001) and negatively associated with the risk of low skeletal muscle mass (OR = 0.53, 95% CI: 0.47-0.60). Structural equation modeling showed that BMI not only had a direct positive effect on ASMI, but also influenced ASMI through metabolic and inflammatory pathways. In the high-BMI group, lipid metabolism had a direct positive effect on ASMI (β = 0.08, P < .001). In contrast, in the low-BMI group, lipid metabolism had a direct negative effect on ASMI (β = -0.08, P < .001) and was also positively associated with ASMI through inflammatory pathways (β = 0.07, P < .001). In this group, glucose metabolism (β = 0.24, P < .001) and protein metabolism (β = -0.08, P < .001) regulated lipid metabolism and indirectly influenced skeletal muscle mass through lipid metabolic pathways. BMI was significantly positively associated with ASMI, with its effects mainly mediated through lipid metabolism and inflammatory pathways, and the pathways differed across BMI groups. These findings highlight lipid metabolism and inflammation as key factors associated with muscle health, facilitating more accurate risk screening and the implementation of targeted prevention and management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.